摘要
【目的】探讨奥氮平治疗精神分裂症(SCZ)对患者糖脂代谢及血常规检验结果的影响。【方法】230例SCZ患者根据治疗方案的不同分为观察组(118例,采用奥氮平治疗)和对照组(112例,采用利培酮治疗)。比较两组患者的疗效,治疗前后的糖脂代谢及血常规指标变化情况。【结果】观察组患者临床有效率与对照组比较,差异无统计学意义(P>0.05)。治疗后,观察组阳性与阴性症状量表(PANSS)各个维度评分均显著低于对照组(P<0.05)。两组患者的空腹血糖(FPG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平均较治疗前均显著降低(P<0.05),甘油三酯(TG)水平较治疗前明显上升(P<0.05),且观察组的各项指标均明显低于对照组(P<0.05)。两组治疗前后血常规各项指标比较,差异均无统计学意义(P>0.05)。【结论】奥氮平与利培酮治疗SCZ患者的总体疗效相当,但奥氮平在改善患者糖脂代谢方面具有更为显著的优势,且对血常规指标无不良影响。
【Objective】To investigate the impact of olanzapine treatment on glycolipid metabolism and blood routine test results in patients with schizophrenia(SCZ).【Methods】A total of 230 SCZ patients were divided into the observation group(118 patients,treated with olanzapine)and the control group(112 patients,treated with risperidone)based on different treatment plans.The efficacy and the changes of glycolipid metabolism and blood routine indicators before and after treatment were compared between the two groups.【Results】The clinical efficacy in the observation group was higher than that in the control group,however,the difference was not statistically significant(P>0.05).After treatment,the scores of the Positive and Negative Syndrome Scale(PANSS)on all dimensions in the observation group were significantly lower than those in the control group(P<0.05).After treatment,the fasting plasma glucose(FPG),total cholesterol(TC),and low-density lipoprotein cholesterol(LDL-C)levels in both groups were significantly lower than before(P<0.05),while triglyceride(TG)level significantly increased(P<0.05).Moreover,the levels of these indicators were significantly lower in the observation group than those in the control group(P<0.05).There were no statistically significant differences in blood routine test results between the two groups before and after treatment(P>0.05).【Conclusion】Olanzapine and risperidone have similar overall therapeutic effects on SCZ patients.However,olanzapine has a more significant advantage in improving glycolipid metabolism and it does not have adverse effects on blood routine indicators.
作者
程卫红
CHENG Weihong(Department of Clinical Laboratory,Rugao Mental Health Center,Nantong Jiangsu 226500)
出处
《医学临床研究》
2025年第2期252-254,共3页
Journal of Clinical Research
